(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.28%) $11.01
(0.55%) $0.808
(-0.96%) $93.00
2 days till quarter result
(bmo 2024-04-22)
Expected move: +/- 4.43%
Live Chart Being Loaded With Signals
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene...
Stats | |
---|---|
Today's Volume | 104 914 |
Average Volume | 243 378 |
Market Cap | 45.51B |
EPS | INR0 ( 2024-04-13 ) |
Next earnings date | ( INR0 ) 2024-04-22 |
Last Dividend | INR1.000 ( 2023-02-08 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 25.32 |
ATR14 | INR0.560 (0.11%) |
Volume Correlation
Aarti Drugs Limited Correlation
10 Most Positive Correlations | |
---|---|
BBL.NS | 0.955 |
RBLBANK.NS | 0.954 |
AIRAN.NS | 0.949 |
PGHH.NS | 0.944 |
KELLTONTEC.NS | 0.94 |
HPL.NS | 0.94 |
PREMEXPLN.NS | 0.939 |
SJVN.NS | 0.938 |
TWL.NS | 0.936 |
POLYCAB.NS | 0.934 |
10 Most Negative Correlations | |
---|---|
LTGILTBEES.NS | -0.947 |
SINTEX.NS | -0.924 |
RAJRILTD.NS | -0.922 |
BOHRAIND.NS | -0.92 |
RAJVIR.NS | -0.911 |
BGLOBAL.NS | -0.906 |
IRISDOREME.NS | -0.906 |
OMAXE.NS | -0.905 |
JPINFRATEC.NS | -0.903 |
SRPL.NS | -0.901 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Aarti Drugs Limited Correlation - Currency/Commodity
Aarti Drugs Limited Financials
Annual | 2022 |
Revenue: | INR27.16B |
Gross Profit: | INR8.28B (30.47 %) |
EPS: | INR17.96 |
Q3 | 2023 |
Revenue: | INR6.06B |
Gross Profit: | INR2.01B (33.12 %) |
EPS: | INR3.99 |
Q2 | 2023 |
Revenue: | INR6.42B |
Gross Profit: | INR2.13B (33.12 %) |
EPS: | INR4.29 |
Q1 | 2023 |
Revenue: | INR6.61B |
Gross Profit: | INR2.15B (32.48 %) |
EPS: | INR5.17 |
Financial Reports:
No articles found.
Aarti Drugs Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR1.000 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.150 | 2003-11-13 |
Last Dividend | INR1.000 | 2023-02-08 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 32 | -- |
Total Paid Out | INR15.88 | -- |
Avg. Dividend % Per Year | 0.23% | -- |
Score | 2.13 | -- |
Div. Sustainability Score | 4.77 | |
Div.Growth Potential Score | 3.36 | |
Div. Directional Score | 4.06 | -- |
Year | Amount | Yield |
---|---|---|
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.250 | 0.18% |
2019 | INR0.250 | 0.17% |
2020 | INR3.00 | 2.03% |
2021 | INR0 | 0.00% |
2022 | INR1.000 | 0.18% |
2023 | INR1.000 | 0.22% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TORNTPHARM.NS | Dividend Junior | 2023-06-23 | Annually | 22 | 0.85% | |
PGHL.NS | Dividend Junior | 2023-11-13 | Annually | 22 | 0.95% | |
JINDALSTEL.NS | Dividend Junior | 2023-08-18 | Sporadic | 25 | 0.25% | |
DELTACORP.NS | Dividend Junior | 2023-07-07 | Annually | 17 | 0.39% | |
SKFINDIA.NS | Dividend Junior | 2023-06-28 | Annually | 22 | 0.93% | |
MGEL.NS | Dividend Junior | 2023-08-08 | Annually | 5 | 0.59% | |
HATSUN.NS | Dividend Junior | 2023-07-27 | Annually | 10 | 0.45% | |
BECTORFOOD.NS | Dividend Junior | 2023-09-22 | Semi-Annually | 4 | 0.39% | |
PSPPROJECT.NS | Dividend Junior | 2023-09-01 | Annually | 8 | 0.49% | |
KEC.NS | Dividend Junior | 2023-07-25 | Annually | 19 | 0.55% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0680 | 1.500 | 8.64 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.201 | 1.500 | 8.88 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 8.41 | 1.000 | 8.00 | 8.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 10.96 | 2.00 | 4.52 | 9.04 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.322 | 1.000 | 7.96 | 7.96 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.105 | 1.000 | 9.91 | 9.91 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 25.91 | 1.000 | 7.48 | 0 | [1 - 100] |
returnOnEquityTTM | 0.201 | 2.50 | 9.28 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 9.04 | [0 - 30] |
dividendYielPercentageTTM | 0.197 | 1.500 | 5.08 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.96 | 2.00 | 6.35 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.373 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0380 | 1.000 | -1.550 | 0 | [0.1 - 0.5] |
Total Score | 3.36 |
Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol C, bisphenol C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators